(Q37347515)

19 August 2017

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia (English)

1 reference

19 August 2017

0 references

1 reference

9

Paul Gaynon

1 reference

19 August 2017

Sima Jeha

1

1 reference

19 August 2017

Bassem Razzouk

2

1 reference

19 August 2017

Michael Rytting

3

1 reference

19 August 2017

Susan Rheingold

4

1 reference

19 August 2017

Edythe Albano

5

1 reference

19 August 2017

Richard Kadota

6

1 reference

19 August 2017

Lori Luchtman-Jones

7

1 reference

19 August 2017

Lisa Bomgaars

8

1 reference

19 August 2017

Stewart Goldman

10

1 reference

19 August 2017

Kim Ritchey

11

1 reference

19 August 2017

Robert Arceci

12

1 reference

19 August 2017

Arnold Altman

13

1 reference

19 August 2017

Kimo Stine

14

1 reference

19 August 2017

Laurel Steinherz

15

1 reference

19 August 2017

Peter Steinherz

16

1 reference

19 August 2017

language of work or name

English

0 references

publication date

3 August 2009

1 reference

Journal of Clinical Oncology

19 August 2017

1 reference

19 August 2017

27

1 reference

19 August 2017

26

1 reference

19 August 2017

4392-4397

1 reference

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Recent advances in pediatric acute lymphoblastic and myeloid leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Progress and controversies in the treatment of pediatric acute myelogenous leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Fifty years of studies of the biology and therapy of childhood leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Biochemical modulation of cytarabine triphosphate by clofarabine.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Neurotoxicity of purine analogs: a review

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

MRC trials in childhood acute myeloid leukaemia

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744276

Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology

2 September 2018

1 reference

12 December 2020

Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia

1 reference

12 December 2020

Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro- beta-D-ribofuranosyl)adenine in CEM cells

1 reference

12 December 2020

FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children

1 reference

12 December 2020

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

1 reference

12 December 2020

Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia

1 reference

12 December 2020

Improved outcome after relapse in children with acute myeloid leukaemia

1 reference

12 December 2020

Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2008.18.8706

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19652076

1 reference